JP2023504209A5 - - Google Patents
Info
- Publication number
- JP2023504209A5 JP2023504209A5 JP2022534708A JP2022534708A JP2023504209A5 JP 2023504209 A5 JP2023504209 A5 JP 2023504209A5 JP 2022534708 A JP2022534708 A JP 2022534708A JP 2022534708 A JP2022534708 A JP 2022534708A JP 2023504209 A5 JP2023504209 A5 JP 2023504209A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- antibody
- subject
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025032847A JP2025084932A (ja) | 2019-12-09 | 2025-03-03 | 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945644P | 2019-12-09 | 2019-12-09 | |
| US62/945,644 | 2019-12-09 | ||
| PCT/US2020/063781 WO2021118999A1 (en) | 2019-12-09 | 2020-12-08 | Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025032847A Division JP2025084932A (ja) | 2019-12-09 | 2025-03-03 | 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504209A JP2023504209A (ja) | 2023-02-01 |
| JP2023504209A5 true JP2023504209A5 (https=) | 2023-12-22 |
| JP7789672B2 JP7789672B2 (ja) | 2025-12-22 |
Family
ID=74046204
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534708A Active JP7789672B2 (ja) | 2019-12-09 | 2020-12-08 | 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体 |
| JP2025032847A Pending JP2025084932A (ja) | 2019-12-09 | 2025-03-03 | 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025032847A Pending JP2025084932A (ja) | 2019-12-09 | 2025-03-03 | 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12612451B2 (https=) |
| EP (1) | EP4073110A1 (https=) |
| JP (2) | JP7789672B2 (https=) |
| KR (1) | KR20220110827A (https=) |
| CN (2) | CN119548622A (https=) |
| AU (1) | AU2020401102A1 (https=) |
| BR (1) | BR112022011280A2 (https=) |
| CA (1) | CA3161271A1 (https=) |
| CO (1) | CO2022009246A2 (https=) |
| MX (1) | MX2022007116A (https=) |
| WO (1) | WO2021118999A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3251727A1 (en) * | 2022-05-04 | 2023-11-09 | Alexion Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISORDER ON THE SPECTRUM OF OPTICAL NEUROMYELITIS |
| WO2025221479A1 (en) * | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| CA2742802C (en) | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| JO3437B1 (ar) * | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
| BR112012027917A2 (pt) | 2010-04-30 | 2017-11-28 | Alexion Pharma Inc | anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano |
| MX340696B (es) * | 2010-04-30 | 2016-07-21 | Alexion Pharma Inc | Anticuerpos anti-c5a y metodos para usar los anticuerpos. |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| IL288931B2 (en) | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| SI3011345T1 (sl) | 2013-08-07 | 2017-12-29 | Alexion Pharmaceuticals, Inc. | Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus) |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| EP3313437A1 (en) * | 2015-06-26 | 2018-05-02 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| EP3402816A1 (en) * | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| ES2999550T3 (en) * | 2017-03-31 | 2025-02-26 | Alexion Pharma Inc | Method for simultaneous quantification of alxn1210 and eculizumab in human serum or urine |
| US20200095307A1 (en) | 2018-09-21 | 2020-03-26 | Alexion Pharmaceuticals, Inc. | Compositions and methods for the treatment of neuromyelitis optica |
| EP4135837A1 (en) | 2020-04-16 | 2023-02-22 | Assistance Publique, Hopitaux De Paris | Methods for treating a complement mediated disorder caused by viruses |
| CN116437913A (zh) | 2020-09-23 | 2023-07-14 | 艾其林医药公司 | 用于治疗补体介导的病症的药物化合物 |
| CA3251727A1 (en) | 2022-05-04 | 2023-11-09 | Alexion Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISORDER ON THE SPECTRUM OF OPTICAL NEUROMYELITIS |
| WO2025221479A1 (en) | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
-
2020
- 2020-12-08 KR KR1020227023328A patent/KR20220110827A/ko active Pending
- 2020-12-08 AU AU2020401102A patent/AU2020401102A1/en active Pending
- 2020-12-08 CN CN202411616594.9A patent/CN119548622A/zh active Pending
- 2020-12-08 JP JP2022534708A patent/JP7789672B2/ja active Active
- 2020-12-08 MX MX2022007116A patent/MX2022007116A/es unknown
- 2020-12-08 EP EP20829482.7A patent/EP4073110A1/en active Pending
- 2020-12-08 BR BR112022011280A patent/BR112022011280A2/pt unknown
- 2020-12-08 WO PCT/US2020/063781 patent/WO2021118999A1/en not_active Ceased
- 2020-12-08 US US17/783,106 patent/US12612451B2/en active Active
- 2020-12-08 CA CA3161271A patent/CA3161271A1/en active Pending
- 2020-12-08 CN CN202080085425.0A patent/CN114867747A/zh active Pending
-
2022
- 2022-07-01 CO CONC2022/0009246A patent/CO2022009246A2/es unknown
-
2025
- 2025-03-03 JP JP2025032847A patent/JP2025084932A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI306458B (en) | Humanized antibodies that recognize beta amyloid peptide | |
| JP2023517236A5 (https=) | ||
| JP7293122B2 (ja) | 補体が媒介する疾患および障害を処置するための方法 | |
| TWI890481B (zh) | 雙特異性抗體 | |
| CN110172098B (zh) | 抗α-突触核蛋白的单克隆抗体及其应用 | |
| US10954292B2 (en) | Anti-PACAP antibody | |
| EP3360896B1 (en) | Antibody to hepatitis b surface antigen and use thereof | |
| RU2003126168A (ru) | Терапевтические связывающие молекулы | |
| JP2021510523A5 (https=) | ||
| JP2023533030A5 (https=) | ||
| JP2014502276A (ja) | アミロイドプラーク関連症状の治療のための組成物及び方法 | |
| JP2023504209A5 (https=) | ||
| JP2022502024A5 (https=) | ||
| US10233256B2 (en) | Antibodies directed to ricin toxin | |
| JP7777071B2 (ja) | 抗α－シヌクレインモノクローナル抗体およびその使用法 | |
| JP2023546504A5 (https=) | ||
| JP2023506779A5 (https=) | ||
| JP2024526742A5 (https=) | ||
| JP2020531041A (ja) | ポリペプチドとポリペプチドに結合される抗体 | |
| JP2024516305A5 (https=) | ||
| JP2024522620A5 (https=) | ||
| JP2023542521A5 (https=) | ||
| TH2101002581A (th) | วิธีการทรีตโรคตาโปนจากไทรอยด์โดยใช้แอนติบอดีชนิด anti-fcrn | |
| WO2024248127A1 (ja) | アレルギー疾患予防・治療薬 | |
| RU2020141137A (ru) | Антитела к коронавирусу и способы применения |